Runcaciguat
| CAS No. | 1402936-61-1 | Cat. No. | BCP42634 |
| Name | Runcaciguat | ||
| Synonyms | BAY 1101042; BAY-1101042 BAY1101042; | ||
| Formula | C23H23Cl2F3NO3 | M. Wt | 489.33 |
| Description | Runcaciguat is a novel, potent, and orally active sGC activator. Runcaciguat activated the sGC reporter cell line with an EC50 value of 11.2 ± 1.0 nM. Pretreatment of the sGC reporter cell line with 30 μM ODQ for 3 h resulted in an increased potency of runcaciguat (EC50 of 2.1 ± 0.07 nM), and treatment of the reporter cells with runcaciguat in combination with the NO donor S-nitroso-N-acetylpenicillamine (SNAP) (10 and 100 nM) showed additive effects. Treatment with runcaciguat resulted in maximal luminescence signals in the range of 50–60% in comparison to the sGC activator cinaciguat. Given the broad impact of oxidative stress in cardiovascular and cardiorenal diseases, runcaciguat might become a new treatment modality for a broad variety of diseases in these indication space but also beyond. | ||
| Pathways | GPCR/G Protein | ||
| Targets | Adenosine Receptor | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.